Загрузка...
Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a...
Сохранить в:
| Опубликовано в: : | Case Rep Urol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Hindawi
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7652618/ https://ncbi.nlm.nih.gov/pubmed/33204569 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8846135 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|